By Pedro Romero, Chief Medical Officer, Novigenix. Two recent original research papers published in the March edition of the New England Journal of Medicine highlight the momentum in screening for colorectal carcinoma (CRC) and high-risk colorectal adenomas. These developments mark a significant milestone in the fight against CRC and signal additional momentum for Novigenix’
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s
Catégorie « Innovation en immuno-transcriptomique pour la détection précoce du cancer colorectal » Le prix récompense l'excellence en matière d'innovation et l'impact dans la détection précoce du cancer LAUSANNE, SUISSE - 22 juillet 2021 - Novigenix SA, une biotech suisse à la pointe du développement et de la commercialisation de solutions en oncologie
La plateforme ImmunoTranscriptomic combine l'identification des signatures d'ARNm de cellules immunitaires avec l'IA pour la détection précoce du cancer LAUSANNE, SUISSE - 7h00, CET, 13 mai 2019 - Novigenix SA, une société pionnière en ImmunoTranscriptomics qui développe et commercialise des produits pour la détection précoce du cancer et la médecine de précision a annoncé
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold